Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial. Burns JM, Morris JK, Vidoni ED, Wilkins HM, et al. Alzheimers Dement 2025;21:e70416.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Burns JM, Morris JK, Vidoni ED, Wilkins HM, et al. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial. Alzheimers Dement 2025;21:e70416.
PMID: 40566796